跳到正文
研踪PaperTrail
← 研踪 PaperTrail

arXiv:2611.26369 · v1

From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening

首次提交 2026-11-20 00:34
版本更新 2026-11-20 00:34
雷达观测 2026-11-20 12:52
arXiv ↗PDF ↗

摘要

Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates. We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins. For the same target or drug, pairs of models produced completely disjoint Top-10 molecule and protein lists in 77.8% and 70.1% of comparisons, respectively. Even where recommendations overlapped, agreement between some systems largely reflected recurring preferences for the same candidates. Published inhibition measurements for 79 molecules and 65 kinases revealed that some systems enriched active candidates, yet their hit yields changed little when recommendations were matched to different drugs or targets, whereas other systems lost substantially more hits. Some of the former systems also rarely ranked both molecules and kinases correctly when two drugs favoured different kinases. We further retrained the same architecture on the same data, with the training objective fixed and random seeds varied. Despite similar test performance, mean pairwise Top-10 overlap on a separate screening catalogue was about two candidates. Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.

作者备注:18 pages, 5 figures and 1 table

AI 论文解读

基于摘要 · 非全文审阅

此版本尚未生成 AI 解读。解读由后台任务生成并按论文版本保存,登录后共享已有结果。

版本差异

目前只收录了一个版本。收录下一版后,可以对照标题、作者、分类和摘要。

观测到的版本

相邻记录可能跳过中间版本;首次发现 v2 及以上也会标为版本更新。

v1 · 2026-11-20 00:34 · 最新观测版本

From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening

Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates. We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins. For the same target or drug, pairs of models produced completely disjoint Top-10 molecule and protein lists in 77.8% and 70.1% of comparisons, respectively. Even where recommendations overlapped, agreement between some systems largely reflected recurring preferences for the same candidates. Published inhibition measurements for 79 molecules and 65 kinases revealed that some systems enriched active candidates, yet their hit yields changed little when recommendations were matched to different drugs or targets, whereas other systems lost substantially more hits. Some of the former systems also rarely ranked both molecules and kinases correctly when two drugs favoured different kinases. We further retrained the same architecture on the same data, with the training objective fixed and random seeds varied. Despite similar test performance, mean pairwise Top-10 overlap on a separate screening catalogue was about two candidates. Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.

查看此版本解读 →查看此版本原文 ↗